FrancophonIA/ELRC3.0 huggingface dataset:
English: Therefore a number of risk minimisation measures in relation to PML are in place for Tysabri.
Danish: Derfor er der iværksat en række risikominimerende foranstaltninger for Tysabri, hvad angår PML.
English: These data confirm previous observations that early PML diagnosis is critical in limiting the degree of permanent brain damage before immune reconstitution can be achieved, and reinforces the need to put in place strategies for the earliest possible identification of potential PML cases, if possible before the development of clinical symptoms of PML.
Danish: Disse data bekræfter tidligere observationer, der tyder på, at tidlig diagnosticering af PML er kritisk med henblik på at begrænse graden af hjerneskade, før immunrekonstitution kan opnås, og de understreger behovet for at iværksætte strategier for så tidligt som muligt at identificere mulige tilfælde af PML så tidligt som muligt og helst før udvikling af kliniske symptomer.
English: PML risk estimation
Danish: Estimering af risikoen for PML
English: MRI is considered to be a sensitive method to identify even small and asymptomatic PML lesions.
Danish: MR-scanning anses for at være en følsom metode til at opdage selv små og asymptomatiske PML-læsioner.
English: It is acknowledged that high expertise is necessary to identify small and asymptomatic PML lesions via MRI.
Danish: Det anerkendes, at der er behov for en høj grad af ekspertise for at kunne opdage små og asymptomatiske PML-læsioner ved hjælp af MR-scanning.
English: Considering the dire diagnosis of PML a high level of vigilance and a low threshold even for invasive diagnostic measures and interventions such as MRI is warranted for managing patients with high risk for PML development.
Danish: I betragtning af den dystre diagnose, som PML er, er det nødvendigt at have et højt overvågningsniveau og en lav grænse for iværksættelse af selv invasive diagnostiske indgreb samt tiltag som MR-scanning med henblik på at kontrollere patienter med høj risiko for udvikling af PML.
English: Available data to date suggest that anti-JCV antibody index is correlated with the risk of PML in anti-JCV antibody positive patients with no prior immunosuppressant use.
Danish: De tilgængelige data tyder på, at anti-JCV-antistof-indekset er korreleret med risikoen for PML hos anti-JCV-antistof-positive patienter uden tidligere brug af immunsupprimerende midler.
English: In addition patients without prior immunosuppressant use and a low antibody index should also be tested every 6 months if they are treated beyond 2 years.
Danish: Derudover bør patienter, der ikke tidligere er blevet behandlet med immunsupprimerende midler, og som har et lavt antistof-indeks, også testes hver 6. måned, hvis de behandles i mere end to år.
English: For patients without prior immunosuppressant use and with high anti-JCV antibody index, no further antibody testing is required, as more frequent MRI screening should be considered if natalizumab treatment is continued for more than 2 years.
Danish: For patienter, der ikke tidligere er blevet behandlet med immunsupprimerende midler, og som har et højt anti-JCV-antistof-indeks, er yderligere antistof-test ikke påkrævet, idet hyppigere MRscreening bør overvejes, hvis natalizumab-behandlingen fortsætter i mere end to år.
English: For natalizumab-treated patients with MS, who are at high risk of PML, brain MRI screening using a protocol that includes FLAIR (fluidattenuated inversion recovery), T2-weighted and diffusion -weighted imaging is recommended.
Danish: For natalizumab-behandlede patienter med multipel sklerose, som har en høj risiko for PML, anbefales MR-screening af hjernen med anvendelse af en protokol, der omfatter FLAIR ("fluid-attenuated inversion recovery"), T2-vægtet og diffusionsvægtet billeddiagnostik.
English: In patients with MRI lesions suggestive for PML, the MRI protocol should be extended to include contrast-enhanced T1-weighted imaging to detect inflammatory features and the possible coincidence of PML and PML-IRIS (Immune Reconstitution Inflammatory Syndrome), particularly during follow up.
Danish: Hos patienter med MR-påviste læsioner, der indikerer PML, bør MR-protokollen udvides til at omfatte kontrastforstærket T1vægtet billeddiagnostik med henblik på at opdage inflammatoriske tegn og muligt sammenfald af PML og PML-IRIS ("Immune Reconstitution Inflammatory Syndrome"), især under opfølgningen.
English: Therefore the CHMP recommends the variation to the terms of the marketing authorisations for Tysabri.
Danish: CHMP anbefaler derfor, at betingelserne for markedsføringstilladelserne for Tysabri ændres.
English: A mock-up of the updated physician information and management guideline can be found annexed to the RMP.
Danish: Et udkast til den opdaterede lægeinformation og behandlingsvejledning er indeholdt i et bilag til risikostyringsplanen.
English: • The PRAC recommended that patients with low anti-JCV antibody index who have not received prior immunosuppressant therapy should be retested every six months once they reach the 2-year treatment point.
Danish: • PRAC anbefaler, at patienter med et lavt anti-JCV-antistof-indeks, som ikke tidligere er blevet behandlet med immunsupprimerende midler, bør testes hver 6. måned efter 2 års behandling.
English: • The PRAC also concluded that, in patients who have not received prior immunosuppressant therapy and are anti-JCV antibody positive, the level of anti-JCV antibody response (index) is associated with risk of developing PML.
Danish: • PRAC konkluderer også, at niveauet af anti-JCV-antistof-respons (indeks) hos patienter, der ikke tidligere er blevet behandlet med immunsupprimerende midler, og som er testet positive for anti-JCV-antistof, har betydning for risikoen for udvikling af PML.
English: Anti-JCV antibody testing
Danish: Test for anti-JCV-antistoffer
English: The Committee, as a consequence, recommended the variation to the terms of the marketing authorisation for Tysabri.
Danish: PRAC anbefaler derfor, at betingelserne for markedsføringstilladelserne for Tysabri ændres.
English: In view of all of the above, the PRAC concluded that the benefit-risk balance of Tysabri remains favourable subject to amendments to the product information and additional risk minimisation measures as described below.
Danish: På grundlag af ovenstående konkluderer PRAC, at benefit/risk-forholdet for Tysabri fortsat er positivt under forudsætning af, at de nedenstående ændringer indføres i produktinformationen, og at der træffes yderligere risikominimerende foranstaltninger som beskrevet nedenfor.
English: The CHMP, as a consequence, considers that the benefit-risk balance of Tysabri remains favourable subject to the amendments to the product information described above.
Danish: CHMP finder følgelig, at benefit/risk-forholdet for Tysabri fortsat er positivt under forudsætning af, at de nævnte ændringer indføres i produktinformationen.
English: Anti-JCV antibody index for guiding MRI monitoring frequency
Danish: Bestemmelse af hyppighed af MR-monitorering på grundlag af anti-JCV-antistof-indeks
English: In general, the positive serostatus results using the first and second generation assays were similar.
Danish: Overordnet set var de positive serostatus-resultater ved anvendelse af første- og andengenerationstest ens. Andengenerationstest har ingen signifikant indvirkning på risikoestimaterne inden for algoritmen.
English: In view of the above, the Committee considered that the benefit-risk balance of Tysabri remains favourable subject to the agreed amendments to the product information and additional risk minimisation measures.
Danish: På grundlag af ovenstående konkluderer PRAC, at benefit/risk-forholdet for Tysabri fortsat er positivt under forudsætning af, at de foreslåede ændringer indføres i produktinformationen, og at der træffes yderligere risikominimerende foranstaltninger.
English: Anti-JCV antibody ELISA
Danish: ELISA-test for anti-JCV-antistoffer
English: • The PRAC also considered it necessary to update the existing educational material, particularly in relation to the risk estimates for development of PML in Tysabri-treated patients.
Danish: navnlig vedrørende risikoestimaterne for udvikling af PML hos Tysabri-behandlede patienter.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 08 July 2005 / 08 July 2010
Danish: DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN 08 juli 2005 / 08 juli 2010
English: 4.6 Adverse reactions (frequency and seriousness)
Danish: 4.6 Bivirkninger (hyppighed og sværhedsgrad)
English: A primary vaccination course may be considered necessary in horses that have not been suitably primed.
Danish: En grundvaccination kan anses for nødvendig i heste som ikke er blevet hensigtsmæssigt grundvaccineret.
English: PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable.
Danish: FORBUD MOR SALG, UDLEVERING OG/ELLER BRUG Ikke relevant.
English: IMMUNOLOGICAL PROPERTIES To stimulate active immunity against Equine influenza ATC-vet code: QI05AA01
Danish: IMMUNOLOGISKE OPLYSNINGER Til stimulering af aktiv immunitet mod equin influenza ATCvet-kode: QI05AA01
English: SPECIAL STORAGE CONDITIONS Store at 2-8 °C, protected from light.
Danish: SÆRLIGE OPBEVARINGSBETINGELSER Opbevares ved 2-8°C, beskyttet mod lys.
English: ADVICE ON CORRECT ADMINISTRATION Allow the vaccine to reach room temperature before use.
Danish: OPLYSNINGER OM KORREKT ANVENDELSE Lad vaccinen opnå rumtemperatur inden brug.
English: Shelf life of the veterinary medicinal product as packaged for sale: 2 years 6.4 Special precautions for storage
Danish: Opbevaringstid for veterinærlægemidlet i salgspakning: 2 år 6.4 Særlige opbevaringsforhold
English: MARKETING AUTHORISATION NUMBER(S) EU/2/05/056/001-004
Danish: MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/05/056/001-004
English: INDICATION(S) Active immunisation of horses against equine influenza.
Danish: INDIKATION(ER) Aktiv immunisering af heste mod equin influenza.
English: 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary Following the administration of a double dose of vaccine, no side-effects other than those described under 4.6 have been observed except for some depression at the day of vaccination 4.11 Withdrawal period(s)
Danish: 4.10 Overdosering (symptomer, nødforanstaltninger, modgift), om nødvendigt Efter administration af en dobbelt vaccinedosis er der ikke set andre bivirkninger end dem, der er beskrevet under afsnit 4.6 bortset fra nogen nedstemthed på vaccinationsdagen.
English: Name and address of the manufacturer of the biological active substance(s)
Danish: Navn og adresse på fremstillerne af de biologisk aktive stof(fer)
English: THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
Danish: TEKSTEN “TIL DYR” OG BETINGELSER ELLER BEGRÆNSNINGER FOR UDLEVERING OG BRUG, om nødvendigt
English: Phosphate buffer
Danish: Phosphatebuffer
English: PACKAGE SIZE 1 dose
Danish: PAKNINGSSTØRRELSE 1 dosis
English: METHODS AND ROUTE OF ADMINISTRATION i.m.
Danish: ANVENDELSESMÅDE OG INDGIVELSESVEJ(E) i.m.
English: The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals.
Danish: D. ANDRE FORHOLD OG BETINGELSER FOR MARKEDSFØRINGSTILLADELSEN Den periodiske, opdaterede sikkerhedsindberetninger (PSUR) cyklus bør nulstilles før indsendelse af 6 månedlige rapporter (der dækker alle godkendte pakningsstørrelser af produktet) for de næste to år, efterfulgt af årlige rapporter for de efterfølgende to år og derefter på 3 års mellemrum.
English: Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Netherlands
Danish: Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Holland
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Prequenza [a clear pictogram of a horse]
Danish: VETERINÆRLÆGEMIDLETS NAVN Equilis Prequenza [et tydeligt piktogram af en hest]
English: Influenza Onset of immunity:
Danish: Influenza Immunitetens indtræden:
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Danish: A. FREMSTILLERE AF DE BIOLOGISK AKTIVE STOFFER OG FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE
English: Pain at the injection site can occur in rare cases, which may result in temporary functional discomfort (stiffness).
Danish: I sjældne tilfælde kan der opstå smerter på injektionsstedet, som kan resultere i forbigående dysfunktion (stivhed).
English: 5 x 1 dose 10 x 1 dose
Danish: 5 x 1 dosis
English: Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection.
Danish: Aktiv immunisering af heste fra 6 måneders alderen mod equin influenza for at reducere kliniske symptomer og udskillelse af virus efter infektion.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA, IF DIFFERENT
Danish: NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN SAMT PÅ DEN INDEHAVER AF VIRKSOMHEDSFODKENDELSE, SOM ER ANSVARLIG FOR BATCHFRIGIVELSE, HVIS FORSKELLIG HERFRA
English: OTHER INFORMATION Cardboard box with 10 glass vials of 1 ml.
Danish: ANDRE OPLYSNINGER Kartonæske med 10 hætteglas af 1 ml.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Prequenza
Danish: VETERINÆRLÆGEMIDLETS NAVN Equilis Prequenza
English: DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Danish: DOSERING FOR HVER DYREART, ANVENDELSESMÅDE OG
English: A/equine-2/South Africa/4/03 (50 AU), A/equine-2/Newmarket/2/93 (50 AU).
Danish: A/equine-2/Sydafrika/4/03 (50 AE), A/equine-2/Newmarket/2/93 (50 AE).
English: In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later).
Danish: I tilfælde af øget smitterisiko eller utilstrækkelig indtagelse af råmælk, kan der gives en ekstra vaccination ved 4 måneders alderen efterfulgt af et fuldt grundvaccinationsforløb (vaccination ved 6 måneders alderen og 4 uger senere).
English: Administer one dose (1ml), by strict intramuscular injection, according to the following schedule: • Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Danish: Indgiv én dosis (1 ml) strikt intramuskulært efter følgende program: • Grundvaccination: Første vaccination fra 6 måneders alderen, anden vaccination 4 uger senere.
English: The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
Danish: Vekslende anvendelse, med 12 måneders interval, af en egnet vaccine mod equin influenza indeholdende stammerne A/equine-2/Sydafrika/4/03 og A/equine-2/Newmarket-2/93 anbefales for at opretholde immunitetsniveauet for influenzakomponenten (se skema).
English: Active substance
Danish: Aktive stoffer
English: WITHDRAWAL PERIOD Zero days
Danish: 10. TILBAGEHOLDELSESTID 0 døgn
English: The first revaccination (third dose) is given 5 months after the primary vaccination course.
Danish: Den første revaccination (tredje dosis) gives 5 måneder efter grundvaccinationen.
English: Intervet International B.V. Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
Danish: Wim de Körverstraat 35 NL-5831 An Boxmeer Holland
English: THE WORDS ‘FOR ANIMAL TREATMENT ONLY'
Danish: TEKSTEN “KUN TIL DYR”
English: 2 weeks after the primary vaccination course Duration of immunity: 5 months after the primary vaccination course 12 months after the first revaccination
Danish: 5 måneder efter grundvaccination 12 måneder efter den første revaccination
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Equilis Prequenza, suspension for injection, for horses
Danish: VETERINÆRLÆGEMIDLETS NAVN Equilis Prequenza, injektionsvæske, suspension til heste
English: Antigenic units Adjuvant Purified saponin
Danish: Adjuvans Renset Saponin
English: INDICATION(S)
Danish: KONTRAINDIKATION(ER)
English: EXPIRY DATE EXP {month/year}
Danish: UDLØBSDATO UDL.D {måned/år}
English: THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN" Keep out of the sight and reach of children
Danish: TEKSTEN “OPBEVARES UTILGÆNGELIGT FOR BØRN” Opbevares utilgængeligt for børn
English: PACKAGE LEAFLET FOR: Equilis Prequenza suspension for injection for horses
Danish: INDLÆGSSEDDEL TIL: Equilis Prequenza, injektionsvæske, suspension til heste
English: Primary vaccination course
Danish: Grundvaccination
English: SPECIAL WARNINGS Read the package leaflet before use
Danish: SÆRLIG(E) ADVARSEL/ADVARSLER, OM NØDVENDIGT Læs indlægssedlen inden brug.
English: ANNEX II A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND ANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Danish: FREMSTILLER(E) AF DE(T) BIOLOGISK AKTIVE STOF(FER) OG FREMSTILLER(E) ANSVARLIG FOR BATCHFRIGIVELSE
English: 50 AU
Danish: 30 måneder
English: It must also not be used together with certain medicines such as:
Danish: Det må heller ikke anvendes sammen med visse lægemidler som f.eks.:
English: A negative test result means that the virus was not found.
Danish: Et negativt testresultat betyder, at der ikke blev fundet virus.
English: Maviret received a marketing authorisation valid throughout the EU on 26 July 2017.
Danish: Maviret fik en markedsføringstilladelse med gyldighed i hele EU den 26. juli 2017.
English: Other information about Maviret
Danish: Andre oplysninger om Maviret
English: Further information on Maviret can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Maviret.
Danish: Yderligere information om Maviret findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/Maviret.
English: Results were similar for genotypes 2 and 4-6.
Danish: Resultaterne var de samme for genotype 2 og 4-6.
English: The recommended dose is three tablets once a day, with food, for 8, 12 or 16 weeks.
Danish: Den anbefalede dosis er tre tabletter én gang dagligt, der tages sammen med mad i 8, 12 eller 16 uger.
English: As for all medicines, data on the use of Maviret are continuously monitored.
Danish: Som for alle lægemidler er data vedrørende brug af Maviret løbende overvåget.
English: Based on data available in adults, it is expected that Maviret is also effective in children with genotypes 5 and 6.
Danish: Baseret på data, der er tilgængelige hos voksne, forventes det, at Maviret også er effektivt hos børn med genotype 5 og 6.
English: The medicine's effectiveness in clearing genotype 3 was slightly lower than for other genotypes (95%).
Danish: Lægemidlets evne til at fjerne genotype 3 var lidt ringere end for andre genotyper (95 %).
English: The most common side effects with Maviret (which may affect more than 1 in 10 people) are headache and tiredness.
Danish: De hyppigste bivirkninger ved Maviret (som kan forekomme hos mere end 1 ud af 10 personer) er hovedpine og træthed.
English: What measures are being taken to ensure the safe and effective use of Maviret?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Maviret?
English: In addition, results showed that the way the medicine was absorbed, modified and removed from the body was similar to that in adults.
Danish: Desuden viste resultaterne, at måden, hvorpå lægemidlet blev absorberet, modificeret og fjernet fra kroppen, var lig den, der er iagttaget hos voksne.
English: The European Medicines Agency therefore decided that Maviret's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede derfor, at fordelene ved Maviret opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: An overview of Maviret and why it is authorised in the EU
Danish: En oversigt over Maviret, og hvorfor det er godkendt i EU
English: Maviret must not be used in patients with severely reduced liver function.
Danish: Maviret må ikke anvendes hos patienter med svært nedsat leverfunktion.
English: For more information about using Maviret, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Maviret, se indlægssedlen, eller kontakt lægen eller apotekspersonalet.
English: Side effects reported with Maviret are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Maviret vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne.
English: The duration of treatment depends on whether patients have liver cirrhosis (scarring of the liver) or whether they have received previous treatments with pegylated interferon and ribavirin, with or without sofosbuvir, or sofosbuvir and ribavirin.
Danish: Behandlingens varighed afhænger af, om patienterne har skrumpelever (ardannelse på leveren), eller om de tidligere har modtaget behandling med pegyleret interferon og ribavirin, med eller uden sofosbuvir eller sofosbuvir og ribavirin.
English: With regard to its safety, Maviret's pattern of side effects raises no particular concern.
Danish: Med hensyn til sikkerheden giver Mavirets bivirkningsmønster ikke anledning til særlige betænkeligheder.
English: What is Maviret and what is it used for?
Danish: Hvad er Maviret, og hvad anvendes det til?
English: The fact that Maviret can be given without ribavirin and without dose adjustments in patients with severe kidney problems is a further advantage in comparison with similar medicines.
Danish: Den omstændighed, at Maviret kan gives uden ribavirin og uden dosisjusteringer hos patienter med svære nyreproblemer, er en yderligere fordel i forhold til lignende lægemidler.
English: Glecaprevir blocks the action of a protein called NS3/4A protease, while pibrentasvir blocks a protein called NS5A.
Danish: Glecaprevir blokerer virkningen af proteinet NS3/4A protease, mens pibrentasvir blokerer et protein, der kaldes NS5A.
English: Why is Maviret authorised in the EU?
Danish: Hvorfor blev Maviret godkendt i EU?
English: Maviret has been shown to be highly effective in clearing the hepatitis C virus from the blood, particularly in patients who have not been treated previously or who do not have cirrhosis.
Danish: Maviret har vist sig at være særdeles effektivt til at fjerne hepatitis C-virus fra blodet, især hos patienter, der ikke tidligere er blevet behandlet, eller som ikke har skrumpelever.
English: What are the risks associated with Maviret?
Danish: Hvilke risici er der forbundet med Maviret?
English: There are 6 varieties (genotypes) of the hepatitis C virus and Maviret has been shown to be effective at clearing all genotypes from the blood.
Danish: Der er seks sorter (genotyper) af hepatitis C-virussen, og Maviret har vist sig at være effektivt til at fjerne alle genotyper fra blodet.
English: By blocking these proteins, Maviret stops the hepatitis C virus from multiplying and infecting new cells.
Danish: Ved at blokere disse proteiner forhindrer Maviret hepatitis C-virusset i at formere sig og inficere nye celler.
English: Maviret is available as tablets that contain 100 mg glecaprevir and 40 mg pibrentasvir.
Danish: Maviret fås som tabletter, der indeholder 100 mg glecaprevir og 40 mg pibrentasvir.
English: • carbamazepine, phenobarbital, phenytoin, primidone (medicines for epilepsy);
Danish: • carbamazepin, phenobarbital, phenytoin, primidon (lægemidler mod epilepsi)
English: • rifampicin (antibiotic usually used to treat tuberculosis);
Danish: • rifampicin (antibiotikum, der normalt bruges til behandling af tuberkulose)
English: In a study in 47 children aged between 12 and 18 years with genotypes 1 to 4 and without cirrhosis, all patients tested negative for the virus after 12 weeks of treatment.
Danish: I et studie med deltagelse af 47 børn i alderen 12-18 år med genotype 1-4 og uden skrumpelever testede alle patienter negative for virusset efter 12 ugers behandling.